Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform

Tumor-infiltrating lymphocyte (TIL) therapy, which involves extracting, expanding, and reinfusing immune cells to target cancer cells, has shown promise in melanoma treatment, but requires optimization for broader efficacy. The success of TIL therapy depends on the recognition of tumor-associated an...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tithi Ghosh Halder, Erin Kelley, Jorge Soria-Bustos, Trason Thode, Serina Ng, Taylor Bargenquast, Alexis Weston, Ryan Rodriguez del Villar, Mohan Kaadige, Erkut Borazanci, Michael Gordon, Justin Moser, Frank Tsai, Saul J. Priceman, Stephen J. Forman, Yan Xing, John A. Altin, Raffaella Soldi, Sunil Sharma
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2026-12-01
coleção:	OncoImmunology
Assuntos:	Adoptive cell therapy immunotherapy PepSeq neoantigens SNAP-TIL tumor-infiltrating lymphocytes
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/2162402X.2026.2684383
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!